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Abstract
Chemical similarity networks are an emerging area of interest in medicinal chemistry,
chemical biology, and systems chemoinformatics that are currently being applied to
drug target prediction, drug repurposing, and drug discovery in the new paradigm of
poly-pharmacology and systems biology. In this chapter, we discuss the network-based
drug target identification and discovery framework called chemical similarity network
analysis pull-down (CSNAP) and its applications. We highlight the utility of CSNAP
in identifying novel antimitotic drugs and their targets through practical case studies.
Keywords: drug discovery, chemical similarity networks, target identification
1. Introduction
Chemical similarity is an important concept in drug discovery used to identify compounds
with similar bioactivities based on structural similarity between two ligands [1, 2]. Once a lead
compound has been discovered from a chemical screen, a drug designer can design a series
of structural analogues with improved pharmaceutical properties. The fundamental principle
behind similarity-based drug discovery is the “chemical similarity principle,” which states
that if two molecules share similar structures, then they will likely have similar bioactivities.
While there are exceptions, correlation between chemical structure and compound activities
has been well established in medicinal chemistry [3]. Consequently, determining whether two
molecules are structurally similar is a prerequisite for similarity-based drug discovery. At a
rudimentary level, the similarity between two ligands can be easily discerned through visual
inspection by identifying common functional  groups,  structural  motifs,  or  substructures.
However, human intervention is often subjective and not suitable for large-scale analysis.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Thus, applying computational algorithms for unbiased chemical similarity comparison and
database searching is essential for a successful drug discovery campaign.
Several computational chemical similarity search algorithms have been developed [1, 4, 5]. The
most commonly used approaches use chemical substructure fingerprints. Non-hashed
structural fingerprints such as MACCS keys or Obabel FP3 fingerprints detect predefined
substructures or functional group patterns in a molecule by mapping common chemical motifs
into binary arrays known as structural keys. To compare the chemical similarity between two
molecules, each molecule is converted into a binary series of 0 and 1, indicating the absence
and presence of a particular substructure. On the other hand, chemical hashed fingerprints
such as Daylight fingerprints or Obabel FP2 fingerprints use path information derived from
molecular graphs to compare chemical structures [4]. While path-based fingerprints usually
confer higher specificity, structural fingerprints can nevertheless be useful for detecting hits
with distinct chemical scaffolds. Once the chemical fingerprints have been determined in a
chemical search and the molecules have been converted to appropriate data representations,
the next step is to evaluate the chemical similarity using a distance metric. Common distance
measures include Euclidean, Manhattan, and Mahalanobis metrics, which have been widely
applied in chemoinformatics and bioinformatics applications [6]. However, in the case of
binary chemical fingerprints, the simplest and most direct distance measure is the Tanimoto
index. Tanimoto metrics calculate the fraction of shared bits between chemical fingerprints in
the range of 0–1. Although there is no universal Tanimoto index cutoff (Tc) to determine
whether two molecules are sufficiently similar, a Tc value of 0.7 is a reasonable starting point
for most chemical searches. Alternatively, statistical scores such as a Z-score can also be
calculated based on the overall Tc score distribution [7].
In addition to 2D fingerprints, 3D chemical similarity fingerprints have also been developed.
3D chemical similarity fingerprints utilize the 3D structural information of the ligands such as
molecular shape, pharmacophore points, or molecular interaction fields (MIF) for structural
similarity comparison. Although 3D chemical similarity comparison can often capture
structural features essential for protein-ligand binding, 3D alignment algorithms often require
extensive optimization procedures to maximize the overlapped volume and are computation-
ally intensive. Alternatively, nonalignment methods based on chemical descriptors such as
GETAWAY or 3D-MoRSE descriptors can also be used [8, 9]. The 3D chemical descriptor is
capable of capturing 3D ligand properties from 2D information and may improve computa-
tional time. However, substantial postvalidation may be required to confirm 3D structural
similarity.
2. Network-based target prediction and drug discovery
The application of chemical similarity searches for ligand bioactivity prediction has recently
gained substantial interest [10]. Due to the high failure rate of many new chemical entities
(NCE) in the late stage of clinical trials, understanding on- and off-target binding of a drug to
predict mechanisms of action and adverse reactions has become crucial for drug discovery
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programs [11]. If the chemical structure of a compound is known, then it is possible to predict
compound bioactivities based on the chemical similarity methods described previously. Drug
targets can be inferred from bioactivity databases with annotated targets sharing the highest
similarity to the target molecules. Many public bioactivity databases are freely available and
can be applied to this application including ChEMBL, PubChem, DrugBank, and Binding
Database to name a few [12–14].
The simplest approach for drug target inference is by a simple chemical similarity search where
the target of a query compound is inferred from the annotated ligand sharing the highest
chemical similarity (Figure 1). However, there are several limitations to this approach. First,
target information for the reference molecules may be incomplete; thus, target inference from
a single molecular entity can miss potential targets from molecules sharing lower chemical
similarity. Likewise, pair-wise target predictions may not provide consistent predictions for a
group of structurally similar ligands. Second, chemical similarity values are not effective at
ranking on and off targets and do not consider the structure-activity relationship (SAR) of
congeneric series. Most importantly, simple ligand-based searches cannot be applied to
analyzing large numbers of ligands such as the unannotated hits from a chemical screen. To
circumvent this shortcoming, we recently proposed a new network target inference approach
based on chemical similarity networks called chemical similarity network analysis pull-down
(CSNAP) [15].
Figure 1. Chemical similarity search using 2D chemical fingerprints.
CSNAP uses a network-based algorithm to predict drug targets and does not rely on absolute
chemical similarity values. It utilizes a scoring function (S-score) to find the consensus targets
of a ligand in its nearest neighbors in a chemical similarity network, which is similar to that
used to predict protein functions in a protein-protein interaction (PPI) network [16]. CSNAP
is compatible with publicly available bioactivity databases, and we routinely use the ChEMBL
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database, which is one of the largest bioactivity databases that contains more than 1 million
compounds with known target annotations. The original CSNAP algorithm applies 2D Obabel
chemical similarity fingerprints (FP2, FP3, FP4, and MACCS) for target predictions. More
recently, we developed CSNAP3D that combines 2D and 3D chemical search algorithms to
improve the chemical search space [17]. CSNAP3D uses a fast 2D chemical similarity search
using either FP2 or FP3 fingerprints to identify sets of hit molecules from large compound
databases, and hit molecules are rescored using a combination of 3D similarity descriptors
based on a combination of shape and pharmacophore. From our benchmark studies, we found
that the CSNAP computational framework was highly accurate and was capable of analyzing
large compound sets with diverse chemical structures. Consistently, the CSNAP application
has been recently extended for large-scale metabolite analysis [18]. We have made the CSNAP
algorithm freely available as the CSNAP web and it can be accessed at http://serv-
ices.mbi.ucla.edu/CSNAP/.
3. CSNAP implementation
3.1. Chemical similarity network algorithms
Mathematically, a chemical similarity network can be considered as a graph G (V, E) where the
vertex V represents compounds and the edge E represents chemical similarity and connects
two compounds if they share a chemical similarity above an arbitrary threshold [19]. The
CSNAP algorithm is performed in three steps: (1) chemical similarity database search, (2)
chemical similarity network construction, and (3) drug target scoring and inference.
3.1.1. Chemical similarity search
Chemical similarity searching is the first step in the CSNAP algorithm (Figure 2A). The
chemical similarity comparisons are performed using various 2D Obabel fingerprints includ-
ing FP2, FP3, MACCS, and others. Query compounds prepared in SMILES or SDF formats are
used as inputs to the CSNAP program. The compounds are searched sequentially against the
ChEMBL database. To identify the ChEMBL compounds most similar to the query, the relative
chemical similarity score is quantified by a Z-value relative to the distribution of the top 100
chemical similarity values. The ChEMBL compounds with a Z-score >2.5 are selected and serve
as the annotated compounds for target inference in the next step.
3.1.2. Chemical similarity network construction
To generate chemical similarity networks, pair-wise chemical similarity values are evaluated
between every pair of compounds. A network edge is established between two ligands
whenever their similarity value is above a predefined threshold (>0.7) (Figure 2B). When large
compound data sets are analyzed by the CSNAP algorithm, structurally diverse compounds
are partitioned into subnetworks of distinct chemical scaffolds, known as “chemotypes.” The
chemical similarity networks can be used to estimate the chemical diversity of input structures
at this stage.
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3.1.3. Drug target scoring and inference
CSNAP infers drug targets using consensus statistics. Specifically, drug targets in the first
neighbor of the query are identified and ranked based on their target annotation frequency
(Figure 2C). A consensus score called an S-score is used to rank the probability that the
predicted target will interact with the query ligand (Figure 2D). There are several advantages
of using this network-based scoring function. First, the S-score eliminates the possibility of
missing target information from the nearest neighbor and considers all possible targets within
the same congeneric series. Second, since the drug target is inferred from the target consensus
and is in agreement with the observed structure-activity relationship, the robustness of the
prediction increases substantially. From our benchmark studies, we showed that this network-
based target inference approach improves the prediction success rate over traditional ap-
proaches that use simple chemical searches [15].
Figure 2. Chemical similarity network analysis pull-down (CSNAP) algorithm for large-scale drug target prediction.
(A) Two-dimensional chemical search of three query ligands (green, red, and yellow) identified nine reference com-
pounds from the bioactivity database. (B) Chemical similarity networks clustered compounds into subnetworks corre-
sponding to three major chemotypes. Note that reference compounds interact with four distinct targets. (C) An S-score
based on consensus statistics is applied to rank the most probable target based on the target annotation frequency of
the first-order neighbor targets. (D) On and off targets are differentiated by ranking the predicted S-scores.
3.2. Case study: CSNAP web server for automated drug target prediction
To reduce concept to practice, we constructed a CSNAP web server for large-scale target
prediction and drug discovery. The CSNAP web includes a front-end graphical user interface
(GUI) that provides user interaction and output visualization, while target prediction is
performed at the back-end by running the CSNAP algorithm.
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3.2.1. CSNAP web input
The CSNAP web server accepts two ligand input formats: SDF and SMILES, which are two of
the most commonly used molecular formats that handle large compound databases. In
addition, a JME molecular editor is also included, which can be used to convert a chemical
structure to a SMILES string on the fly (Figure 3A). Several chemical fingerprints are provided
to perform chemical comparisons during the search and network clustering steps, including
Obabel FP2, FP3, PF4, and MACCS fingerprints (Figure 3B). Obabel FP2 fingerprints use a
path-based algorithm and are more specific than FP3, FP4, and MACCS that utilize a prede-
fined set of substructures for chemical searches. On the other hand, when structural analogues
are not available in the chemical database, FP3 can instead be used to search structurally
distinct chemicals with similar bioactivities. To perform chemical searches, the chemical
similarity cutoff needs to be defined. Here, CSNAP web supports a combination of absolute
cutoff based on Tanimoto coefficient (Tc > 0.7) and relative chemical similarity cutoff based on
a Z-score. From our experience, the default option using a Z-score cutoff of 2.5 will be optimal
for most initial CSNAP predictions.
Once the query ligands and chemical search parameters have been defined, the CSNAP
algorithm will search the ChEMBL compound activity database to identify structurally similar
compounds for target inference (Figure 3B). The ChEMBL database assigns targets to a
compound based on the level of target specificity (confidence score). Similarly, the compounds
are also classified based on the assay type from which they are derived, including biochemical,
functional, or ADMET assays. These database parameters will also need to be selected to
perform the CSNAP analysis.
3.2.2. CSNAP web output
The CSNAP output page consists of three main panels: (1) chemical similarity networks, (2)
chemical structure information, and (3) ligand-target interaction fingerprint (LTIF) (Figure 3C).
3.2.3. Chemical similarity networks
The chemical similarity networks panel displays the generated chemical networks using the
CSNAP algorithm based on input ligands. The chemical similarity network connects query
(red) and annotated ligands (gray) from the ChEMBL database, and the targets are inferred
using consensus statistics. For large compound sets, the number of generated chemical clusters
can be used to estimate the chemical diversity of the sets. To retrieve additional information
regarding a specific ligand, the user can click on the node and the relevant information will be
displayed in the chemical structure information panel.
3.2.4. Chemical structure information
The chemical structure information panel displays the chemical information selected from the
chemical similarity network panel. The panel consists of several columns that include chemical
structure information (chemical ID, chemical structure, SMILES string, InChI key) and the
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predicted target information (target name and UniProt ID). In the ChEMBL prediction column,
the predicted targets of each compound are ranked by the S-score.
Figure 3. Drug target prediction using the CSNAP web server: (A) construct a query molecule using the JME molecular
editor. (B) The molecule is converted to a SMILES string and entered into the CSNAP query submission page. (C) The
CSNAP output page consists of three main panels: (1) the chemical similarity network, (2) the chemical structure infor-
mation, and (3) the ligand-target interaction fingerprint (LTIF).
3.2.5. Ligand-target interaction fingerprint (LTIF)
To analyze the results from large-scale target prediction searches, the ligand-target interaction
fingerprint (LTIF) is provided in the CSNAP web output. The LTIF panel displays the predicted
S-score of each compound mapped against the predicted targets, and the color intensity of the
LTIF heatmap is correlated with the S-score values. The LTIF can be used to infer compounds
sharing similar target binding profiles, which may have similar bioactivity. By clicking on the
LTIF button at the top of the LTIF panel, a separate window is created that shows the target
spectrum and Gene Ontology (GO) term search derived from the LTIF analysis.
3.2.6. Target spectrum and Gene Ontology (GO) search
To further differentiate primary targets from off-targets in the LTIF, the CSNAP web also
computes a target spectrum, by summing the S-score (∑S) of all analyzed compounds for each
target column (Figure 4). For a single compound analysis, the highest peak corresponds to the
Chemical Similarity Networks for Drug Discovery
http://dx.doi.org/10.5772/65106
59
primary target. Similarly, for multi-ligand analysis, the highest peak corresponds to the most
abundant target in the set. To determine the functional role of the predicted targets, the Gene
Ontology (GO) search result is also provided (Figure 4). GO is a popular bioinformatics tool
that maps genes into functions based on controlled vocabulary (GO terms) and has been widely
used for pathway analysis of functional genomic data [20]. Here, CSNAP web incorporates a
GO search in target predictions as a strategy for posttarget selection and validation. The GO
terms can be used to further select relevant targets in a cell-based or phenotype-based screen
based on the knowledge of anticipated molecular etiology including cellular components,
molecular functions, and biological process. Smaller subsets of targets can then be filtered for
additional experimental validation.
Figure 4. Posttarget validation using Gene Ontology (GO) analysis in the CSNAP web. (Top) Target spectrum. (Bottom)
GO search results.
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4. Application of CSNAP for drug target prediction and discovery
4.1. CSNAP validation
The CSNAP algorithm was validated using 206 known drugs from the directory of useful
decoy (DUD) set [21]. The benchmark set included 46 angiotensin-converting enzyme (ACE),
47 cyclin-dependent kinase 2 (CDK2), 23 heat-shock protein 90 (HSP90), 34 HIV reverse-
transcriptase (HIVRT), 25 HMG-CoA reductase (HMGA), and 31 poly [ADP-ribose] polymer-
ase (PARP) inhibitors. Using the default search criteria (fingerprint: FP2, Tc = 1, Z-score = 2.5),
we evaluated the ability of the CSNAP algorithm to accurately predict the designated targets
of each compound based on the S-score rankings. CSNAP analysis of the 206 compounds
showed that the chemical similarity network clustered the drugs into distinct subnetworks,
corresponding to diverse chemical scaffolds (chemotypes) (Figure 5). For a given subnet-
work, the S-score was further used to predict the drug target of each compound based on their
network connectivity with the reference ligands. The prediction results were then compared
with those obtained by the similarity ensemble approach (SEA) [22]. The CSNAP algorithm
gave an overall 80–94% true-positive prediction rate (TPR) in comparison with SEA (63–75%)
based on the top 1, top 5, and top 10 ranking of target predictions. In particular, CSNAP
substantially improved the target prediction rate for promiscuous ligands such as CDK2 and
ACE inhibitors (92 and 96%) compared to the SEA approach (30 and 65%) (Figure 6).
Figure 5. CSNAP2D clustering of 206 benchmark compounds consisting of six known drug classes from the directory
of useful decoy (DUD) set.
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Figure 6. Performance comparison between CSNAP and SEA. CSNAP achieved improved prediction accuracy (TPR)
for promiscuous drug classes like ACE, CDK2, and HIVRT inhibitors.
4.2. Target prediction of hits from an antimitotic chemical screen
We applied the CSNAP algorithm to predict the drug targets of a set of 212 compounds that
were inhibitors of cell division [23]. CSNAP clustering of the mitotic compounds resulted into
85 chemical similarity subnetworks (Figure 7A). To identify the most common targets within
the set, we applied the LTIF analysis. The target spectrum derived from the LTIF revealed four
broad classes of mitotic targets including fatty acid desaturases (SCD, SCD1, and FADS2),
ABL1 kinase, non-receptor-type tyrosine phosphatases (PTPN7, PTPN12, PTPN22, PTPRC,
and ACP1), and beta tubulins. In particular, the target spectrum showed that beta tubulin had
the largest peak height and was the most prominent protein target for the mitotic compounds.
Further analysis showed that 51 compounds were associated with tubulin-targeting chemo-
types. The predicted drug targets were validated by comparing siRNA-treated and drug-
treated mitotic phenotypes in cell culture using immunofluorescence microscopy. In addition,
in vitro tubulin polymerization assays were used to determine the effects of these compounds
on microtubule formation. Among the 51 tested compounds, 31 compounds showed a
perturbation of microtubule polymerization >25%, and thus, the CSNAP algorithm achieved
a prediction accuracy of >70%.
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Figure 7. Discovery of novel tubulin-targeting drugs (compounds 1–7). (A) CSNAP analysis of 212 mitotic drugs iden-
tified seven novel tubulin destabilizing compounds. (B) The compounds induced a G2/M cell cycle arrest and de-
creased cell viability in cell-based assays. (C) Discovery of compound 3 as the most potent compound in the series. (D)
A mass spectrometry-based competition assay was used to show that compound 3 and podophyllotoxin (PPT) compet-
ed for binding to tubulin in contrast to vincristine (VCT). (E) Compound-treated (1–3) and colchicine-treated (COL)
cells displayed a tubulin destabilizing effect in comparison with the tubulin stabilizing effect of taxol (TX).
4.3. Discovery of novel tubulin-targeting antimitotics
Using a negative selection strategy, we identified seven novel tubulin-targeting agents that
were active in our tubulin polymerization assay but had not been associated with known
tubulin chemotypes (Figure 7A). The seven compounds were analogues of phenyl-sulfanyl-
thiazol-acetamide scaffolds that exhibit various degrees of tubulin destabilizing effects
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through a mechanism similar to that of the tubulin destabilizing agent colchicine. The most
potent compound, compound 3, in the series exhibited a cytotoxic effect in the nano-molar
range (EC50: G2/M = 33 nM; EC50: cell death = 60 nM) when evaluated in cell viability and G2/
M arrest assays (Figure 7B, C) [15]. The predicted mechanism was validated using a mass
spectrometry-based competition assay where both the selected analogues and podophyllo-
toxin, a known colchicine site binder, competed for binding to tubulin in contrast to the
negative control vincristine that interacted with a distant site in beta tubulin (Figure 7D) [24].
Likewise, both compound-treated and colchicine-treated cells displayed a tubulin destabiliz-
ing phenotype, characterized by rapid shortening of microtubule length and the disappearance
of microtubule polymer mass (Figure 7E).
Figure 8. Binding mechanism of a novel tubulin destabilizing chemotype (compounds 1–7). (A) Pharmacophore align-
ment between compound 1 and colchicine (COL) showed a consensus pharmacophore. (B) Docking of compound 1 in
the colchicine site using the tubulin crystal structure (PDB code: 1SA0) revealed colchicine-like interactions with criti-
cal residues (Met259, Cys241). (C) Docking of the seven analogues into the colchicine site showed similar interactions.
4.4. Characterization of novel tubulin-targeting antimitotics
To investigate how the novel antimitotics interacted with beta tubulin, we performed structural
alignments between compound 6 and colchicine and identified a consensus pharmacophore
between the two molecules (Figure 8A). Further docking of compound 6 into the colchicine
binding site also showed that both compound 6 and colchicine interacted with common
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residues, including the 2 and 10 methoxy groups and 9-keto group that interacted with Met259
and Cys241 of beta tubulin, respectively (Figure 8B). Similarly, all seven analogues docked into
the same site through similar interactions. Interestingly, the elucidated binding modes could
be used to explain the observed SAR. For example, the increased potency of compound 7 and
8 in comparison with 6 could be attributed to the hydrophilic interactions between the N-
propyl and N-phenyl groups with Leu248 and Lys352 within the subpockets of the colchicine
binding site (Figure 8C).
5. CSNAP3D: a 3D upgrade to the CSNAP approach
Chemical similarity searches based on 2D chemical structures have several limitations. First,
compounds with distinct scaffolds can exhibit similar bioactivity due to “scaffold hopping”
by interacting with a common receptor [25, 26]. Second, although 2D fingerprints based on
substructure or fragment searches have the potential to detect scaffold hopping, the scaffold
enrichment rate is low. Furthermore, 2D searches do not capture essential features of protein-
ligand interactions in three-dimensional space. Consequently, 3D chemical searches based on
the three-dimensional information of the ligands will offer additional opportunities to discover
novel compounds.
5.1. 3D chemical similarity search
The most common approach to compare ligand similarity in 3D is by shape superposition,
which maximizes the Gaussian volume overlap between two ligands [27]. Alternatively, ligand
alignments that use molecular interaction field (MIF) or pharmacophore have also been
proposed [28, 29]. These approaches take into account the shared chemical features arranged
in three-dimensional space. To identify the optimal 3D chemical descriptors, we performed an
unbiased screen of diverse 3D chemical descriptors based on molecular shapes or pharmaco-
phores. Using 206 benchmark compounds from the DUD set, we tested the ability of each 3D
descriptor to enrich class-specific scaffolds ranked by respective similarity scores. The lowest
energy conformer of each ligand was generated using the MOE program. The results showed
that 3D chemical descriptors using a combination of shape and pharmacophore features
achieved the highest enrichment rate and ligand alignment accuracy compared to those based
on shape or pharmacophore alone. This observation agrees with our current understanding
that shape complementary and chemical matching are essential for the protein-ligand binding
process.
We subsequently developed a 3D chemical similarity search method called “ShapeAlign” that
utilized two open-source softwares: “Shape-it” and “Align-it” [30]. Similar to the combo score
implemented in the ROCS program, the ShapeAlign algorithm also used a combination of
shape and pharmacophore for 3D chemical searches. However, ShapeAlign incorporated a 2D
fingerprint similarity score as an integral part of the searching process. Given a ligand with a
pre-generated 3D conformation, the ShapeAlign algorithm first detects ligands from the
chemical database with the highest shape matching evaluated by a shape Tanimoto index. The
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hit molecules are then aligned and rescored according to the degree of pharmacophore
matching using the Align-it program.
5.2. Drug target prediction using CSNAP3D
We incorporated the “ShapeAlign” algorithm into our CSNAP program called “CSNAP3D”
to cluster chemical structures and predict drug targets based on 3D ligand similarity. To
evaluate CSNAP3D performance, we assessed the average true-positive rate (TPR) and false-
positive rate (FPR) of predicting drug targets for the 206 benchmark compounds. The result
showed that CSNAP3D achieved a TPR of >95% at 0.85 Tanimoto cutoff in comparison with
other 2D target prediction approaches including CSNAP2D, SEA, and PASS approaches [17].
A comparison of CSNAP3D and CSNAP2D generated networks showed that diverse 2D
scaffold subnetworks were clustered into smaller subsets of 3D chemical networks, suggesting
that CSNAP3D could be used to identify scaffold hopping ligands not identifiable by conven-
tional 2D methods (Figure 9).
Figure 9. CSNAP3D clustered 34 distinct HIVRT NNRTI chemotypes into a shape-based chemical similarity network.
The figure shows that many NNRTIs are scaffold hopping ligands to a common nucleotidyltransferase binding site.
The 3D alignment between ligands was based on molecular shape and pharmacophore points (HD: hydrogen donor,
HA: hydrogen acceptor, AR: aromatic, LP: lipophilic).
5.2.1. Target prediction of HIVRT inhibitors
As further validation, we presented a case study of predicting targets for a set of HIVRT
inhibitors using the CSNAP3D algorithm. HIVRT inhibitors can be classified as nucleoside-
based analogues (NRTIs) or non-nucleoside-based analogues (NNRTIs) [31]. In particular,
NNRTIs have been difficult drug classes for computational dug target prediction due to the
chemical diversity of the drug classes where many compounds are scaffold hopping ligands
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that bind to a common nucleotidyltransferase binding site. Although 3D ligand-based target
predictions that use either the alignment or nonalignment methods have been attempted, many
of these approaches yielded low predictability. Here, we applied CSNAP3D to predict the drug
targets of 34 structurally diverse HIVRT NNRTIs and compared the prediction results with
the CSNAP2D approach (Figure 9). Initial 2D chemical similarity network analysis clustered
the 34 NNRTIs into 20 structurally diverse chemical similarity scaffolds. Further LTIF analysis,
by mapping target prediction S-scores to the heatmap, showed that more than 20 compounds
did not have a prediction. The NNRTIs were similarly analyzed by the CSNAP3D program
using the ShapeAlign algorithm. In contrast, all the 34 ligands were clustered by CSNAP3D
into a single shape-based chemical similarity network, suggesting that many NNRTIs are
scaffold hopping ligands to a common binding site. LTIF analysis showed that 33 of NNRTIs
were correctly predicted, thus achieving a TPR of >97%. In particular, 3D chemical similarity
networks correctly identify three FDA-approved NNRTIs, namely efavirenz, nevirapine, and
tivirapine whose structure alignment agreed with previous crystal structures and SAR studies
(Figure 9). In addition, several novel scaffold hopping pairs were also identified (Figure 9).
5.2.2. Discovery of novel taxol scaffold hopping ligands
Taxol (paclitaxel) is a well-known anticancer natural product derived from the Yew tree, whose
antiproliferative effect was first discovered in 1960s from an NCI anticancer drug screening
campaign [32]. Taxol has since been found to be effective for treating a wide range of cancers
including ovarian, breast, lung, bladder, prostate, melanoma, esophageal, and other solid
tumors. However, the efficacy of taxol has been limited by severe side effects, toxicity, and
synthetic feasibility. Thus, identification of low-weight taxol mimetics with more tolerable
drug profiles is critical. While several taxol mimetics have been discovered including Synstab
B and GS-164, both discovered by chemical screening, their binding mechanisms have
remained undetermined [33, 34].
Here, we sought a rational approach to discover taxol mimetics using the CSNAP3D algorithm
based on our existing structural knowledge of the original taxol molecule. CSNAP3D analysis
of the 212 mitotic compounds from a chemical screen identified 42 potential taxol mimetics
linked to 30 taxol structural conformers. Seven predicted taxol mimetics were found to be true
positives with a >25% fold change in optical density when tested in tubulin polymerization
assays in vitro and four compounds shared a consensus chemotype by co-localizing within one
chemical similarity subnetwork. The structural alignment of the four selected molecules with
taxol showed that they shared a similar T-shape conformation despite a simpler scaffold
(Figure 10A). Docking studies showed that the increase in microtubule polymerization activity
could be attributed to the phenyl moiety of these ligands, which was capable of forming a pi–
pi stacking interaction with the critical residue His229 within the taxane site (Figure 10B).
Three of the compounds demonstrated cytotoxic and antimitotic effects in cell culture with a
potency <5 µM. Similarly, all the compounds displayed a similar tubulin stabilizing phenotype,
characterized by microtubule aster formation in immunofluorescence microscopy studies
(Figure 10C).
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Figure 10. Structure-based discovery of taxol mimetics. (A) CSNAP3D analysis of 212 mitotic compounds from a cell-
based screen identified four low molecular weight taxol (TX) mimetic analogues. (B) Compound 8 (8) demonstrated a
fast tubulin polymerization rate at 50 µM similar to taxol (Tax) at 5 µM in comparison with colchicine (Col). (C) Com-
pound 8 displayed a tubulin stabilizing phenotype, characterized by microtubule aster formation in immunofluores-
cence microscopy studies.
6. Conclusions and future directions
Chemical similarity is an important concept in medicinal chemistry and drug discovery to
identify similar compounds with improved bioactivities. Here, we have expanded on this
concept to chemical similarity network theory, where descriptive network statistics and graph
topology can be applied to large-scale analysis of chemical diversity, bioactivities, and target
identification. To demonstrate the utility of this approach, we have implemented the CSNAP
algorithm, which can be used for large-scale compound analysis and target predictions.
Analogous to protein function prediction in PPI networks, we applied consensus statistics to
identify the common targets of each query ligand. We showed that this scoring function
outperforms several target prediction methods based on simple chemical similarity searches.
To address the challenge of scaffold hopping, where structurally diverse ligands can poten-
tially interact with a common receptor, we developed the CSNAP3D algorithm as a CSNAP
extension. CSNAP3D searches chemical structure using the “ShapeAlign” protocol, which
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utilizes a combination of shape and pharmacophore descriptors. We found that CSNAP3D
improves target prediction, particularly for challenging drug classes such as HIVRT NNRTIs
that showed high structural diversity and are scaffold hopping ligands. Finally, we successfully
applied CSNAP3D to rationally discover low molecular weight taxol mimetics, which exhibit
a taxol-like anticancer mechanism and potentially possess improved transport and pharma-
cokinetic properties than its natural counterpart.
The current CSNAP framework can be extended in several directions. For instance, consen-
sus scoring can be expanded by considering higher-order neighbors, which has been dem-
onstrated to improve prediction accuracy in PPI networks. Similarly, graph theoretical
approaches based on maximum network flow and other global optimization approaches
can be applied for target assignments [35]. To improve posttarget validation, high through-
put functional genomics data can be incorporated to aid in the identification of critical tar-
gets relevant to a disease pathway. One example is multiplayer network approaches that
integrate drug, target, and annotation interaction networks to enhance target predictions
and validations [36]. While CSNAP3D has substantially improved the predictability of
CSNAP2D, the algorithm is limited to receptors with bound ligands and the ligand align-
ment is based on the lowest energy conformer. This shortcoming can be circumvented by
considering multi-conformer networks that correlate ligand conformation with target spe-
cificities. Likewise, pseudo-ligands generated as the mirror image of an orphan receptor can
be considered for receptor deorphanization.
In conclusion, chemical similarity networks are an emerging field in ligand-based drug dis-
covery where the collective properties of a ligand can be easily dissected using descriptive
network statistics and graph topology. Here, we presented a new network-based approach
for drug discovery and target identification called chemical similarity network analysis
pull-down (CSNAP) and a new CSNAP framework called CSNAP3D. The CSNAP compu-
tational framework represents a new concept in computational drug discovery with practi-
cal application in target identification and drug discovery. We anticipate that the CSNAP
approach will stimulate further work in systems and network-based drug discovery that
will aid in the discovery of novel drugs for the treatment of cancer and other important
diseases.
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